End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
14.38
CNY
|
+3.68%
|
|
-2.11%
|
-39.61%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,731
|
21,269
|
20,829
|
15,754
|
14,881
|
8,908
|
-
|
-
|
Enterprise Value (EV)
1 |
13,731
|
21,269
|
22,701
|
17,255
|
15,810
|
10,182
|
10,333
|
10,249
|
P/E ratio
|
39.5
x
|
26.6
x
|
18
x
|
10.9
x
|
48.4
x
|
12.7
x
|
9.21
x
|
8.34
x
|
Yield
|
0.58%
|
0.38%
|
0.4%
|
0.8%
|
0.25%
|
0.74%
|
1.3%
|
1.1%
|
Capitalization / Revenue
|
1.62
x
|
2
x
|
1.59
x
|
0.78
x
|
1.11
x
|
0.62
x
|
0.55
x
|
0.51
x
|
EV / Revenue
|
1.62
x
|
2
x
|
1.74
x
|
0.85
x
|
1.18
x
|
0.71
x
|
0.64
x
|
0.59
x
|
EV / EBITDA
|
12.7
x
|
12.6
x
|
10.1
x
|
4.93
x
|
11.3
x
|
4.63
x
|
3.89
x
|
3.69
x
|
EV / FCF
|
160
x
|
19.5
x
|
30.1
x
|
24.4
x
|
12.7
x
|
65.3
x
|
14.4
x
|
8.87
x
|
FCF Yield
|
0.63%
|
5.12%
|
3.32%
|
4.09%
|
7.85%
|
1.53%
|
6.97%
|
11.3%
|
Price to Book
|
3.45
x
|
4.53
x
|
3.57
x
|
2.12
x
|
1.97
x
|
1.11
x
|
0.99
x
|
0.93
x
|
Nbr of stocks (in thousands)
|
620,458
|
620,458
|
620,458
|
626,898
|
624,979
|
619,450
|
-
|
-
|
Reference price
2 |
22.13
|
34.28
|
33.57
|
25.13
|
23.81
|
14.38
|
14.38
|
14.38
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,453
|
10,649
|
13,083
|
20,282
|
13,408
|
14,321
|
16,240
|
17,391
|
EBITDA
1 |
1,079
|
1,686
|
2,255
|
3,502
|
1,396
|
2,197
|
2,656
|
2,780
|
EBIT
1 |
774.6
|
1,320
|
1,838
|
2,823
|
842.2
|
1,436
|
1,839
|
2,182
|
Operating Margin
|
9.16%
|
12.4%
|
14.05%
|
13.92%
|
6.28%
|
10.03%
|
11.33%
|
12.54%
|
Earnings before Tax (EBT)
1 |
771.2
|
1,317
|
1,791
|
2,544
|
798.3
|
1,328
|
1,797
|
2,081
|
Net income
1 |
347.3
|
802.9
|
1,163
|
1,434
|
307.5
|
710.1
|
977.9
|
1,079
|
Net margin
|
4.11%
|
7.54%
|
8.89%
|
7.07%
|
2.29%
|
4.96%
|
6.02%
|
6.2%
|
EPS
2 |
0.5600
|
1.290
|
1.863
|
2.298
|
0.4918
|
1.135
|
1.561
|
1.725
|
Free Cash Flow
1 |
85.95
|
1,090
|
753
|
706.4
|
1,242
|
156
|
720
|
1,155
|
FCF margin
|
1.02%
|
10.23%
|
5.76%
|
3.48%
|
9.26%
|
1.09%
|
4.43%
|
6.64%
|
FCF Conversion (EBITDA)
|
7.97%
|
64.64%
|
33.4%
|
20.17%
|
88.93%
|
7.1%
|
27.11%
|
41.54%
|
FCF Conversion (Net income)
|
24.75%
|
135.72%
|
64.75%
|
49.25%
|
403.83%
|
21.97%
|
73.63%
|
107.08%
|
Dividend per Share
2 |
0.1280
|
0.1300
|
0.1350
|
0.2000
|
0.0600
|
0.1070
|
0.1867
|
0.1585
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3,744
|
4,649
|
6,104
|
4,876
|
4,653
|
3,232
|
3,610
|
3,450
|
3,116
|
2,973
|
3,737
|
3,665
|
3,478
|
8,496
|
4,172
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
60.03
|
1,082
|
1,501
|
814.1
|
-575
|
-
|
419.2
|
252.7
|
-190.2
|
102.9
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
1.6%
|
23.28%
|
24.6%
|
16.69%
|
-12.36%
|
-
|
11.61%
|
7.32%
|
-6.1%
|
3.46%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
23.17
|
-
|
-
|
-
|
1,192
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.78%
|
-
|
-
|
-
|
14.03%
|
-
|
EPS
2 |
-0.0900
|
1.209
|
1.810
|
0.8800
|
-1.600
|
0.2554
|
0.4600
|
0.1300
|
-0.3600
|
0.0371
|
0.4400
|
0.3400
|
0.2500
|
0.6500
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/15/22
|
4/26/22
|
8/26/22
|
10/26/22
|
4/12/23
|
4/26/23
|
8/30/23
|
10/27/23
|
4/19/24
|
4/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
1,872
|
1,501
|
929
|
1,274
|
1,425
|
1,342
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.8302
x
|
0.4288
x
|
0.6655
x
|
0.5799
x
|
0.5364
x
|
0.4826
x
|
Free Cash Flow
1 |
85.9
|
1,090
|
753
|
706
|
1,242
|
156
|
720
|
1,155
|
ROE (net income / shareholders' equity)
|
9.04%
|
18.6%
|
22.1%
|
21.7%
|
4.1%
|
8.19%
|
10.2%
|
10.2%
|
ROA (Net income/ Total Assets)
|
3.24%
|
6.94%
|
8.31%
|
7.83%
|
-
|
4.08%
|
4.72%
|
5.15%
|
Assets
1 |
10,709
|
11,575
|
13,996
|
18,325
|
-
|
17,406
|
20,718
|
20,944
|
Book Value Per Share
2 |
6.420
|
7.570
|
9.420
|
11.90
|
12.10
|
13.00
|
14.50
|
15.50
|
Cash Flow per Share
2 |
0.7800
|
2.490
|
2.120
|
2.620
|
3.060
|
2.700
|
2.490
|
3.100
|
Capex
1 |
397
|
457
|
565
|
933
|
680
|
561
|
546
|
513
|
Capex / Sales
|
4.7%
|
4.3%
|
4.32%
|
4.6%
|
5.07%
|
3.92%
|
3.36%
|
2.95%
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Last Close Price
14.38
CNY Average target price
24.22
CNY Spread / Average Target +68.42% Consensus |
1st Jan change
|
Capi.
|
---|
| -39.61% | 1.23B | | -16.99% | 8.55B | | +65.23% | 4.24B | | -1.63% | 2.54B | | -41.76% | 2.35B | | -8.53% | 1.89B | | -19.29% | 1.55B | | +9.54% | 1.13B | | +19.57% | 955M | | -5.12% | 924M |
Medical & Diagnostic Laboratories
|